ICG-fluorescence Imaging for Intraoperative Breast Cancer Margins Evaluation: a Dose-timing Study

Recruiting now · Not applicable

Conditions studied: Breast Cancer

In brief

Designed in five-arm, single-center, prospective randomized, observational- interventional, open-label study which will evaluate patients with histological proven early-stage BC that will undergo planned BCS for their local treatment. Two preoperatively times frames will be used for the administration of a total of 5 different indocyanine green (ICG) dose as a single dose-patient arm. In the first time frame (intraoperative arms), the dose of, respectively 0.125 mg/kg and 0.25 mg/kg of ICG will be administered at induction anesthesia (at least 20 minutes before the BCS) in two subgroups. In the second time frame, (preoperative arms), the dose of, respectively, 0.5 mg/kg, 1 mg/kg, and 2 mg/kg of ICG will be administered 24 h before surgery in 3 subgroups.

Key facts

Study ID

NCT06227338

Run by

Jules Bordet Institute

People needed

250

Starts

2024-02-12

Expected to finish

2026-01-01

Last updated by the study team

2025-02-26

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• female;
• age of ≥18 years;
• histological diagnosis of ductal invasive breast cancer;
• a primary early-stage invasive breast cancer (cT1 and/or cT2, assessed clinically and/or radiologically), without prior BC surgery of the actually affected breast;
• ECOG Performance Status (PS) 0 or 1;
• signed informed consent form (ICF) obtained prior to any study related procedure.

You may not qualify if…

• advanced invasive breast cancer (cT3 and/or cT4);
• in situ breast cancer disease;
• lobular invasive breast cancer (at histology);
• invasive breast cancer treated by neoadjuvant chemotherapy and/or endocrine therapy;
• prior history of invasive or breast cancer of the actually affected breast in the past;
• history of allergy or hypersensitivity to investigational product (active substance or ingredients);
• history of allergy to iodine or to shellfish;
• have apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal, or disseminated autonomy of the thyroid gland;
• documented coronary disease
• advanced renal insufficiency (serum creatinine >1.5 mg/dL);
• chronic liver disease with the Child-Pugh class B or C ;
• concurrent medication which reduces or increases the elimination of indocyanine green dye (ie, anticonvulsants, haloperidol, and heparin) during the 2 weeks before the expected operation;
• pregnant or lactating women;
• inability to give informed consent.

Where it is running

• Jules Bordet Institute — Brussels, Belgium (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.